Re Agreement

RNS Number:0713T
Fulcrum Pharma PLC
10 December 2003


For immediate release                                           10 December 2003


                               FULCRUM PHARMA PLC

                   Signs First Preferred Supplier Arrangement
               A three year agreement with Addex Pharmaceuticals

Hemel Hempstead, UK, 10 December 2003: Fulcrum Pharma PLC (AIM: FUL), the drug
development and strategic outsourcing services company, is pleased to announce
the signing of its first preferred supplier arrangement in which Fulcrum takes
an equity stake in its partner and receives fees for service.  The three year
agreement with Addex Pharmaceuticals SA, the Swiss pharmaceutical company, is
focused on addiction and other central nervous system disorders, to provide drug
development services for the Addex portfolio of novel compounds.

Under the terms of this agreement Fulcrum will be responsible for the provision
of drug development resource and expertise to support Addex in the development
of its product portfolio over the next 3 years and to assist Addex in building
its own clinical capability.

As part of this agreement a letter of intent has been issued whereby Fulcrum
will subscribe for shares in Addex's next round of financing.


Jon Court, CEO of Fulcrum Pharma, commented:

"We are extremely impressed with Addex and their portfolio of compounds, and
delighted to have been chosen as their development partner.  This agreement
represents a significant step in the development of Fulcrum's partnership
strategy."

Upon signing the agreement, Vincent Mutel, CEO of Addex Pharmaceuticals,
remarked:

"This three year partnership is a great opportunity for us to solve our clinical
resourcing needs and at the same time build knowledge of clinical development
within Addex. In addition, we view Fulcrum's commitment and investment as a
strong validation of our portfolio."

_____________________________________________

For further information, please contact :

Fulcrum Pharma PLC
Jon Court, Chief Executive                                  08707 107152
Geoffrey Smith, Finance Director                            08707 104501

Addex Pharmaceuticals
Karen Wilson                                                [phone]

Buchanan Communications
Mary-Jane Johnson                                           020 7466 5000

Seymour Pierce Limited
Jonathan Wright                                             020 7107 8000


Notes to Editors:

About Fulcrum Pharma
Fulcrum Pharma plc is an independent, drug development company that is the first
to offer global virtual drug development and strategic outsourcing services to
the pharmaceutical industry.

The Company has expertise in the design, execution and delivery of drug
development programmes and relies on state of the art information technology and
infrastructure in the supply of its services.

Through Fulcrum's services to its clients, the Directors believe that there is
the capacity to deliver products faster and more efficiently to the global
pharmaceutical market. Fulcrum does this by using its skills in the design of
drug programmes that deliver the necessary information for decision-making and
product registration. In so doing, Fulcrum works closely with its clients to
meet their strategic R&D goals.

Fulcrum Pharma is listed on the Alternative Investment Market of the London
Stock Exchange having successfully floated in March 2000.


About Addex Pharmaceuticals SA

Addex Pharmaceuticals SA is a pharmaceutical company, based in Geneva,
Switzerland, committed to the discovery, development and marketing of novel
therapeutic compounds for the treatment of addiction and other central nervous
system (CNS) disorders. The Addex team combines expertise in the field of
addiction with broad experience in drug development.

The Company has specific know-how for the development of compounds which have
modulatory activity on specific CNS targets.  Addex is applying this know-how to
develop novel compounds that are expected to be useful for the treatment of a
number of CNS disorders, including drug dependence.

Addex is backed by venture capitalists: Index Ventures, Sofinnova Partners and
Techno Venture Management.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

AGRTLBLTMMJMBBJ